Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Shanghai Huaota Biopharmaceutical Co., Ltd.

Clinicaltrial registered29 Oct 2026

Shanghai Huaota Biopharmaceutical Co., Ltd.

29 Oct 2026: Trial registered · HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
29 Oct 2026
Title
HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer
Conditions
First-line pMMR Endometrial Cancer
Phase
Phase 3
Study Type
Interventional
Status
Recruiting
Countries
China
Country
China
Reference
NCT07902999
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Shanghai Huaota Biopharmaceutical Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Shanghai Huaota Biopharmaceutical Co., Ltd. in our registers.

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.